Supriya Lifescience Share Price
Supriya Lifescience Share Price Today
As of 25 Jul 2026, Supriya Lifescience share price is ₹840.50. The stock opened at ₹832.90, compared to its previous close of ₹832.90. During today's trading session, Supriya Lifescience share price moved in the range of ₹820.00 to ₹846.00, with an average price of ₹833.00 for the day. Looking at its last 52-week, the stock has touched a low of ₹545.50 and a high of ₹1,085.00. On the performance front, Supriya Lifescience share price has increased by 17.38% over the last six months and is up 21.90% on a year-on-year basis.
Supriya Lifescience Returns Calculator
Supriya Lifescience Shareholder Returns
Supriya Lifescience Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,68,842.00 | 36.73 | 5.05 | 14.85% | 0.55 | 18.72% | 18.85 | 0.91% | 0.56 | 10.90 |
| Divis Laboratories | 1,93,860.00 | 61.36 | 9.40 | 16.19% | 0.00 | 21.00% | 9.43 | 0.50% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,92,687.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,12,593.00 | 33.55 | 3.27 | 11.27% | 0.00 | 14.95% | 423.36 | 0.93% | 0.44 | 43.52 |
| Zydus Lifesciences | 1,11,082.00 | 17.39 | 3.23 | 19.69% | 0.35 | 20.30% | 3.70 | 0.11% | 0.39 | 35.38 |
| Lupin | 1,09,553.00 | 19.83 | 4.71 | 27.01% | 0.03 | 27.44% | 3.51 | 0.78% | 0.61 | 129.18 |
| Mankind Pharma | 1,05,607.00 | 1.05 | 0.12 | 12.65% | 0.42 | 12.97% | 5.05 | 0.05% | 0.54 | 49.37 |
| Dr. Reddy's Laboratories | 97,364.90 | 30.58 | 2.56 | 11.07% | 0.18 | 12.54% | 377.96 | 0.69% | 0.41 | 38.68 |
| Aurobindo Pharma | 88,508.40 | 25.27 | 2.34 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 84,727.30 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
Supriya Lifescience Financials
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹696.49 | ₹570.34 | ₹460.94 | ₹530.05 |
| Other Income | ₹9.82 | ₹10.64 | ₹9.49 | ₹7.58 |
| Total Revenue | ₹706.30 | ₹580.98 | ₹470.43 | ₹537.63 |
| Total Expenses | ₹457.82 | ₹415.29 | ₹346.94 | ₹330.38 |
| Profit Before Tax | ₹248.48 | ₹165.69 | ₹123.49 | ₹207.25 |
| Tax | ₹60.52 | ₹46.58 | ₹33.63 | ₹55.44 |
| Profit After Tax | ₹187.96 | ₹119.11 | ₹89.86 | ₹151.81 |
| EPS - Basic | ₹23.35 | ₹14.80 | ₹11.16 | ₹18.86 |
| EPS - Diluted | ₹23.35 | ₹14.80 | ₹11.16 | ₹18.86 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹248.48 | ₹165.69 | ₹123.49 | ₹207.25 |
| Income before WC changes | ₹262.22 | ₹168.09 | ₹128.10 | ₹214.12 |
| Change in Assets | -₹45.30 | -₹15.24 | -₹34.61 | -₹96.31 |
| Change in Liabilities | ₹6.94 | -₹1.90 | ₹0.80 | -₹8.04 |
| Change in WC | -₹38.36 | -₹17.14 | -₹33.82 | -₹104.35 |
| Cash flow from Operations | ₹164.68 | ₹113.31 | ₹63.61 | ₹48.80 |
| Cash flow from Investing | -₹152.24 | -₹173.57 | -₹123.65 | -₹59.82 |
| Cash flow from Financing | -₹8.23 | -₹22.36 | -₹10.28 | ₹149.65 |
| Total Cash Flow | ₹4.20 | -₹82.63 | -₹70.33 | ₹138.63 |
| Cash (Start of the year) | ₹74.96 | ₹157.58 | ₹227.91 | ₹89.28 |
| Cash (End of the year) | ₹79.15 | ₹74.96 | ₹157.58 | ₹227.91 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹675.28 | ₹523.43 | ₹355.39 | ₹237.22 |
| Current Assets | ₹437.04 | ₹398.02 | ₹464.89 | ₹497.54 |
| Total Assets | ₹1,112.31 | ₹921.45 | ₹820.28 | ₹734.76 |
| Current Liabilities | ₹82.16 | ₹77.11 | ₹95.78 | ₹99.70 |
| Net Current Asset | ₹354.88 | ₹320.91 | ₹369.11 | ₹397.84 |
| Non-Current Liabilities | ₹33.39 | ₹28.98 | ₹25.04 | ₹19.38 |
| Equity Capital | ₹996.76 | ₹815.37 | ₹699.46 | ₹615.69 |
| Total Equity & Liabilities | ₹1,112.31 | ₹921.45 | ₹820.28 | ₹734.76 |
About Supriya Lifescience
Supriya Lifescience Limited is an Indian pharmaceutical company. It was established in 1987 and is headquartered in Mumbai. It is a prominent global producer of active pharmaceutical ingredients (APIs).
In API manufacturing, the company specialises in products across diverse therapeutic segments such as anti-histamines, anti-allergics, vitamins, anaesthetics and anti-asthmatics.
The company has a worldwide presence, reaching 86 countries. It’s domestic operations are spread across 12 states in India. Its product portfolio of active pharmaceutical ingredients includes more than 38 products.
The market capitalisation of Supriya Lifescience Limited stood at over ₹2,400 crore as of January 19, 2024. Supriya Lifescience share price has gained 42% in the last three years.
Supriya Lifescience Limited business operations
Supriya Lifescience Limited is a major supplier of active pharmaceutical ingredients (APIs) globally. It ensures efficient procurement from both Indian and global sources including China, South Korea and Belgium.
The company serves many well-known global pharmaceutical firms. A few of them are Syntec Do Brasil LTDA, American International Chemical Inc, AT Planejamento E Desenvolvimento De Negocios Ltd, Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd, among others. Approximately 45% of the company's revenue comes from its top 10 customers.
In FY23, the company generated 20% of its revenues domestically and 80% from exports. Asia and Europe contributed the most to the company's revenue, followed by Latin America and North America.
The company operates a backwards-integrated production facility located in Lote, Parshuram in Maharashtra. It spans 23,806 square meters and is divided into four blocks based on therapy. The facility includes a reactor with a capacity of 547 KL. It has approvals from various regulatory bodies including USFDA, EDQM and EUGMP. The company has also received marketing auithorisations from AIFA in Italy, TGA in Australia, BfArM in Germany, KFDA in Korea, PMDA in Japan, SFDA in China and COFEPRIS in Mexico.
The facility features designated sections for warehouse, production, finished products and dedicated blocks for different therapeutic segments. As part of the company's capacity expansion plan, the facility is projected to reach approximately 1000+ KL by 2024. The facility in Lote also houses a DSIR-approved R&D facility. The company has plans to expand its product segments within its portfolio and is in the process of establishing two new R&D centres.
In FY23, Supriya Lifescience Limited expanded its manufacturing capabilities by incorporating four new laboratories into its existing facility at Lote. Construction is also underway for a manufacturing facility with a capacity of 330 KL. It is anticipated to become operational by February 2024.
By the end of FY23, the company had submitted 15 active Drug Master Files (DMFs) to the USFDA. It also submitted nine active Certificates of Suitability (CEPs) to the European Directorate for the Quality of Medicines and Healthcare for its API products.
Supriya Lifescience Financial Highlights
- Revenue: Supriya Lifescience reported revenue of ₹839.37 crore in FY26 vs ₹706.31 crore in FY25. It showed an increase of 18.84% on a yearly basis.
- Operating Profit: Supriya Lifescience reported an operating profit of ₹274.78 crore in FY26 vs ₹248.48 crore in FY25. It showed an increase of 10.58% on a year-on-year basis.
- Net Profit: Supriya Lifescience reported a net profit of ₹209.12 crore in FY26 vs ₹187.96 crore in FY25. It showed an increase of 11.26% on a yearly basis.
Supriya Lifescience Quarterly Result Highlights
- Supriya Lifescience reported revenue of ₹280.01 crore in Mar 2026, compared with ₹209.05 crore in Dec 2025, representing an increase of 33.94% on a quarter-on-quarter (QoQ) basis.
- Supriya Lifescience reported an operating profit of ₹92.13 crore in Mar 2026, compared with ₹66.92 crore in Dec 2025, representing an increase of 37.67% on a quarter-on-quarter (QoQ) basis.
- Supriya Lifescience reported a profit of ₹74.23 crore in Mar 2026, compared with ₹49.68 crore in Dec 2025, reflecting an increase of 49.42% on a QoQ basis.
- The earnings per share (EPS) of Supriya Lifescience stood at ₹23.35 during Mar 2026.
Similar Stocks
FAQs on Supriya Lifescience Share Price
What is Supriya Lifescience share price today?
Supriya Lifescience share price is ₹840.50 as on 24 Jul, 2026, 15:41 IST.
How has the Supriya Lifescience share price performed in the past?
In the last 1 year, Supriya Lifescience delivered a return of 21.90%. The Supriya Lifescience share price hit a high of ₹1,085.00 and low of ₹545.50.
How much is the Mutual Fund shareholding in Supriya Lifescience shares?
The Mutual Fund Shareholding in Supriya Lifescience was 1.29% at the end of Jun 2026.
What is the the 52-week high and low of Supriya Lifescience shares ?
The 52-week high and low of Supriya Lifescience share is ₹1,085.00 and ₹545.50 as of 24 Jul, 2026.
What is the market cap of Supriya Lifescience?
The market capitalisation of Supriya Lifescience is ₹6,700.60 Crores as on 24 Jul, 2026.
What are the stock symbols of Supriya Lifescience?
The stock symbol of Supriya Lifescience is SUPRIYA on the NSE, 543434 on the BSE, and the ISIN is INE07RO01027.
What was yesterday's closing price of Supriya Lifescience shares ?
Supriya Lifescience shares closed yesterday at ₹832.90 on NSE & ₹832.55 on BSE
How to buy Supriya Lifescience shares?
To buy Supriya Lifescience shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Supriya Lifescience shares on Holidays?
No, shares of Supriya Lifescience or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Supriya Lifescience shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Supriya Lifescience?
The PE and PB ratio of Supriya Lifescience is 32.05 and 5.59 respectively, as on 24 Jul, 2026, 15:41 IST.